ICU Medical Inc (OQ:ICUI)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: 951 Calle Amanecer
Tel: 1-646-2771254
IR: See website
Key People
Vivek Jain
Chairman of the Board, Chief Executive Officer
Brian Michael Bonnell
Chief Financial Officer, Treasurer
Christian B. Voigtlander
Chief Operating Officer
Virginia Sanzone
Corporate Vice President, General Counsel and Secretary
Daniel Woolson
Corporate Vice President, General Manager - Infusion Systems
Business Overview
ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company's product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.
Financial Overview
For the three months ended 31 March 2020, ICU Medical Inc revenues decreased 1% to $328.6M. Net income decreased 46% to $16.8M. Revenues reflect IV Solutions segment decrease of 8% to $104.3M, Critical Care segment decrease of 4% to $12.4M, United States segment decrease of 7% to $230.2M. Net income also reflects OTHER INCOME (EXPENSE), net - Balancing decrease from $1.9M (income) to $11.6M (expense).
Employees: 8,000 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $3,601M as of Mar 31, 2020
Annual revenue (TTM): $1,264M as of Mar 31, 2020
EBITDA (TTM): $253.39M as of Mar 31, 2020
Net annual income (TTM): $86.87M as of Mar 31, 2020
Free cash flow (TTM): $59.61M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 20,832,404 as of Apr 30, 2020
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization